Related Experiment Video
Updated: Jul 5, 2026
12:24
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
Published on: June 3, 2014
Recombinant clotting factors.
1Department of Pediatrics and Communicable Diseases, University of Michigan, L2110 Women's Hospital, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA. ummdswp@med.umich.edu
Thrombosis and Haemostasis
|May 2, 2008
Summary
The development of recombinant clotting factors revolutionized hemophilia care, offering safer and more accessible treatments. This advancement has improved patient outcomes and expanded therapeutic options for bleeding disorders.
Area of Science:
- Biotechnology
- Hematology
- Molecular Biology
Background:
- The advent of recombinant DNA technology in the early 1980s enabled the production of functional clotting factors.
- Challenges in producing recombinant clotting factors involved complex post-translational modifications essential for their function.
- Viral contamination of plasma-derived factors accelerated the adoption of recombinant alternatives.
Purpose of the Study:
- To review the development and impact of recombinant clotting factors in hemophilia care.
- To highlight the role of recombinant DNA technology in addressing current and future challenges in hemophilia treatment.
- To discuss the expansion of recombinant factor use to other inherited bleeding disorders.
Main Methods:
- Review of historical development and clinical application of recombinant clotting factors.
- Analysis of the impact of recombinant factor VIII and IX on hemophilia therapy, including prophylaxis.
- Examination of advancements like recombinant factor VIIa for patients with inhibitors.
Main Results:
- Recombinant factors VIII and IX have successfully replicated the function of plasma-derived counterparts.
- Widespread use of recombinant therapies has increased factor concentrate availability and enabled aggressive treatment strategies.
- Recombinant factor VIIa provides an option for hemophilia patients with inhibitors.
Conclusions:
- Recombinant DNA technology is pivotal for advancing hemophilia care, focusing on cost reduction, global accessibility, and improved protein function.
- Ongoing development of recombinant clotting factors offers new alternatives for various inherited bleeding disorders.
- Recombinant clotting factors have transformed hemophilia management, improving patient lives and treatment paradigms.
Related Concept Videos
01:09Coagulation
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:09Recombinant DNA
Overview